Last updated 22 Oct 2025
Frequently Asked Questions
- Is VDPHL01 hormone-free?
- Yes. Preclinical data suggest no systemic 5-alpha-reductase inhibition; detailed endocrine panels are pending.
Source: Veradermics patent WO2025/072131 (accessed 22 Oct 2025) - How does it differ from finasteride?
- Finasteride lowers circulating DHT; VDPHL01 aims to block DHT impact locally at the follicle without hormonal shifts. See the comparison table for details.
- What results can be expected?
- No peer-reviewed efficacy data yet. Preliminary internal reports indicate increased non-vellus hair count after two months, but numbers are undisclosed.
Source: Veradermics investigator webcast, 15 Jul 2025 - What side effects have been seen so far?
- Safety profile is not public. No severe adverse events were reported in the Phase 1 study (n = 24), but long-term data are pending.
Source: Investigator Brochure v1.3 (redacted), 2025 - Can VDPHL01 be combined with minoxidil?
- No interaction studies released. Combination use may be explored after Phase 3 completion.
- How do I join a clinical trial?
-
- Review inclusion/exclusion criteria at NCT06724614.
- Contact the nearest study site via the registry’s “Contacts and Locations” section.
- Complete a pre-screening questionnaire; final eligibility is confirmed by the investigator.
- Will the drug be prescription-only?
- Yes. If approved, it will require a physician’s prescription similar to finasteride.
- Expected price?
- No pricing information until late-stage regulatory review. Comparable systemic therapies range US $25–60/month (generic finasteride) to US $250/month (brand novel agents).
- First countries to launch?
- The sponsor indicates simultaneous filings in the US and EU; expansion to Asia-Pacific would follow.
- Is VDPHL01 suitable for women?
- The current trial enrols only men (18–55 y). Safety and efficacy in females remain unknown.
- Popular search queries
-
- “VDPHL01 release date”
- “Where to buy VDPHL01”
- “VDPHL01 price”
- “VDPHL01 clinical trial reviews”
- “VDPHL01 official website”
- “When will VDPHL01 be available for purchase?”
This information is for general knowledge and does not replace professional medical advice.
Sources
- ClinicalTrials.gov: NCT06724614 (accessed 22 Oct 2025)
- Veradermics Investigator Brochure v1.3 (2025)
- World Congress for Hair Research webcast (15 Jul 2025)